Market Cap | 43.09B | P/E | 62.63 | EPS this Y | 4.80% | Ern Qtrly Grth | -9.30% |
Income | 845.63M | Forward P/E | 46.77 | EPS next Y | 15.80% | 50D Avg Chg | 4.00% |
Sales | 3.78B | PEG | 4.33 | EPS past 5Y | 16.73% | 200D Avg Chg | 12.00% |
Dividend | N/A | Price/Book | 39.42 | EPS next 5Y | 10.85% | 52W High Chg | -8.00% |
Recommedations | 2.50 | Quick Ratio | 0.90 | Shares Outstanding | 82.31M | 52W Low Chg | 64.00% |
Insider Own | 0.94% | ROA | 22.77% | Shares Float | 81.39M | Beta | 1.33 |
Inst Own | 95.94% | ROE | 63.25% | Shares Shorted/Prior | 2.38M/2.41M | Price | 519.18 |
Gross Margin | 60.41% | Profit Margin | 22.34% | Avg. Volume | 454,379 | Target Price | 531.19 |
Oper. Margin | 32.41% | Earnings Date | Oct 31 | Volume | 759,719 | Change | -2.46% |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Piper Sandler | Neutral | Aug 14, 24 |
BTIG | Buy | Jul 25, 24 |
Stifel | Hold | Jun 24, 24 |
Morgan Stanley | Overweight | May 14, 24 |
Barclays | Overweight | May 2, 24 |
JP Morgan | Overweight | Feb 6, 24 |
Barclays | Overweight | Feb 6, 24 |
Piper Sandler | Neutral | Jan 30, 24 |
Goldman Sachs | Buy | Jan 17, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
POLEWACZYK JAMES F | Executive Vice Presi.. Executive Vice President | Dec 07 | Sell | 521.77 | 11,636 | 6,071,316 | 10,050 | 12/08/23 |
POLEWACZYK JAMES F | Executive Vice Presi.. Executive Vice President | Dec 07 | Option | 247.86 | 11,636 | 2,884,099 | 21,686 | 12/08/23 |
MAZELSKY JONATHAN JAY | President and CEO President and CEO | Dec 04 | Sell | 513.23 | 7,128 | 3,658,303 | 79,233 | 12/06/23 |
MAZELSKY JONATHAN JAY | President and CEO President and CEO | Dec 04 | Option | 79.54 | 13,424 | 1,067,745 | 86,361 | 12/06/23 |
Lane Michael | Executive Vice Presi.. Executive Vice President | Nov 07 | Option | 129.24 | 1,728 | 223,327 | 5,774 | 11/08/23 |
MAZELSKY JONATHAN JAY | President and CEO President and CEO | Aug 31 | Sell | 512.01 | 13,424 | 6,873,222 | 72,925 | 09/05/23 |
MAZELSKY JONATHAN JAY | President and CEO President and CEO | Aug 31 | Option | 79.54 | 13,424 | 1,067,745 | 86,349 | 09/05/23 |
POLEWACZYK JAMES F | Executive Vice Presi.. Executive Vice President | Aug 29 | Sell | 510.23 | 22,909 | 11,688,859 | 10,038 | 08/31/23 |
POLEWACZYK JAMES F | Executive Vice Presi.. Executive Vice President | Aug 29 | Option | 141.69 | 16,909 | 2,395,836 | 32,947 | 08/31/23 |
Lane Michael | Executive Vice Presi.. Executive Vice President | Aug 03 | Sell | 510 | 16,027 | 8,173,770 | 4,034 | 08/07/23 |
Lane Michael | Executive Vice Presi.. Executive Vice President | Aug 03 | Option | 175.6 | 16,027 | 2,814,341 | 20,061 | 08/07/23 |
AYERS JONATHAN W | Director Director | May 18 | Option | 79.54 | 20,000 | 1,590,800 | 147,039 | 05/22/23 |
AYERS JONATHAN W | Director Director | May 18 | Sell | 491.23 | 20,000 | 9,824,600 | 137,039 | 05/22/23 |
AYERS JONATHAN W | Director Director | May 09 | Option | 178.26 | 560 | 99,826 | 141,894 | 05/11/23 |
Underberg Sharon E. | EVP, GC & Corporate.. EVP, GC & Corporate Secretary | May 05 | Option | 206.94 | 483 | 99,952 | 4,245 | 05/08/23 |
SZOSTAK M ANNE | Director Director | May 05 | Sell | 474.99 | 2,000 | 949,980 | 4,700 | 05/08/23 |
MCKEON BRIAN P | EVP, CFO and Treasur.. EVP, CFO and Treasurer | May 05 | Option | 178.26 | 560 | 99,826 | 29,605 | 05/08/23 |
Vandebroek Sophie V. | Director Director | May 04 | Sell | 469.02 | 2,187 | 1,025,747 | 872 | 05/05/23 |
Vandebroek Sophie V. | Director Director | May 04 | Option | 206.62 | 2,187 | 451,878 | 3,059 | 05/05/23 |
MAZELSKY JONATHAN JAY | President and CEO President and CEO | May 04 | Option | 178.26 | 560 | 99,826 | 73,301 | 05/05/23 |
Turner Kathy V | Senior Vice Presiden.. Senior Vice President | Feb 14 | Sell | 504.16 | 2,000 | 1,008,320 | 7,380 | 02/16/23 |
Turner Kathy V | Senior Vice Presiden.. Senior Vice President | Feb 14 | Option | 13.26 | 2,732 | 36,226 | 9,380 | 02/16/23 |
SZOSTAK M ANNE | Director Director | Dec 02 | Option | 160.28 | 2,000 | 320,560 | 2,000 | 12/06/22 |
SZOSTAK M ANNE | Director Director | Dec 02 | Sell | 428.55 | 740 | 317,127 | 1,260 | 12/06/22 |
MAZELSKY JONATHAN JAY | President & CEO President & CEO | Nov 14 | Sell | 434.65 | 10,500 | 4,563,825 | 70,805 | 11/16/22 |
MAZELSKY JONATHAN JAY | President & CEO President & CEO | Nov 14 | Option | 62 | 18,998 | 1,177,876 | 81,305 | 11/16/22 |
Turner Kathy V | Senior Vice Presiden.. Senior Vice President | Nov 10 | Option | 192.6 | 13,877 | 2,672,710 | 15,490 | 11/14/22 |
Turner Kathy V | Senior Vice Presiden.. Senior Vice President | Nov 10 | Sell | 422.91 | 13,877 | 5,868,722 | 6,923 | 11/14/22 |
MAZELSKY JONATHAN JAY | President & CEO President & CEO | Nov 07 | Option | 52 | 24,002 | 1,248,104 | 75,537 | 11/09/22 |
MAZELSKY JONATHAN JAY | President & CEO President & CEO | Nov 07 | Sell | 382.07 | 13,230 | 5,054,786 | 62,307 | 11/09/22 |
Underberg Sharon E. | EVP, GC & Corp. Secr.. EVP, GC & Corp. Secretary | Feb 17 | Option | 206.94 | 483 | 99,952 | 2,987 | 02/18/22 |
MCKEON BRIAN P | Executive VP & CFO Executive VP & CFO | Feb 16 | Option | 141.60 | 706 | 99,970 | 28,154 | 02/17/22 |
AYERS JONATHAN W | Director Director | Feb 15 | Sell | 509.7 | 250 | 127,425 | 629,490 | 02/17/22 |
MCKEON BRIAN P | Executive VP & CFO Executive VP & CFO | Nov 08 | Option | 67.85 | 16,310 | 1,106,634 | 32,627 | 11/10/21 |
MCKEON BRIAN P | Executive VP & CFO Executive VP & CFO | Nov 08 | Sell | 629.21 | 16,310 | 10,262,415 | 26,317 | 11/10/21 |
Turner Kathy V | Senior Vice Presiden.. Senior Vice President | May 26 | Sell | 547 | 2,900 | 1,586,300 | 4,866 | 05/26/21 |
AYERS JONATHAN W | Director Director | May 20 | Option | 79.54 | 7,632 | 607,049 | 661,333 | 05/20/21 |
AYERS JONATHAN W | Director Director | May 12 | Sell | 541.74 | 512 | 277,371 | 653,701 | 05/12/21 |
HENDERSON REBECCA M | Director Director | Feb 25 | Option | 160.28 | 3,046 | 488,213 | 17,742 | 02/25/21 |
HENDERSON REBECCA M | Director Director | Feb 25 | Sell | 513.41 | 3,046 | 1,563,847 | 14,696 | 02/25/21 |
Claflin Bruce L. | Director Director | Feb 18 | Option | 122.64 | 7,027 | 861,791 | 7,331 | 02/18/21 |
Claflin Bruce L. | Director Director | Feb 18 | Sell | 537.04 | 7,331 | 3,937,040 | 02/18/21 | |
MCKEON BRIAN P | Executive VP & CFO Executive VP & CFO | Feb 17 | Option | 0 | 2,642 | 27,356 | 02/17/21 | |
MCKEON BRIAN P | Executive VP & CFO Executive VP & CFO | Feb 17 | Sell | 539.58 | 1,307 | 705,231 | 24,714 | 02/17/21 |
Lane Michael | Executive Vice Presi.. Executive Vice President | Feb 17 | Option | 0 | 984 | 4,768 | 02/17/21 | |
Lane Michael | Executive Vice Presi.. Executive Vice President | Feb 17 | Sell | 545 | 850 | 463,250 | 3,624 | 02/17/21 |
Vandebroek Sophie V. | Director Director | Feb 16 | Option | 160.28 | 3,046 | 488,213 | 6,367 | 02/16/21 |
Vandebroek Sophie V. | Director Director | Feb 16 | Sell | 538.2 | 3,046 | 1,639,357 | 3,321 | 02/16/21 |
MCKEON BRIAN P | Executive VP & CFO Executive VP & CFO | Nov 10 | Sell | 475.43 | 10,000 | 4,754,300 | 18,050 | 11/10/20 |
MAZELSKY JONATHAN JAY | President & CEO President & CEO | Nov 09 | Option | 70.77 | 2,868 | 202,968 | 41,413 | 11/09/20 |